ANHUI BAIWO BIOTECHNOLOGY CO., LTD. – Trademark Portfolio

Entity Type: 99

ANHUI BAIWO BIOTECHNOLOGY CO., LTD. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include GUSUSA. The owner is based in BOZHOU CITY, ANHUI PROVINCE.

NO. 29 EAST, HUAHONGYUAN NATURAL

VILLAGE, QIANLIHE ADMINISTRATIVE VILLAGE, ZHAOQIAO, TOWNSHIP, QIAOCHENG DISTRICT,

BOZHOU CITY, ANHUI PROVINCE , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

GUSUSA
GUSUSA
Registered 2020

Trademark Classifications

ANHUI BAIWO BIOTECHNOLOGY CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does ANHUI BAIWO BIOTECHNOLOGY CO., LTD. have?

ANHUI BAIWO BIOTECHNOLOGY CO., LTD. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does ANHUI BAIWO BIOTECHNOLOGY CO., LTD. file in?

ANHUI BAIWO BIOTECHNOLOGY CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are ANHUI BAIWO BIOTECHNOLOGY CO., LTD.'s most well-known trademarks?

ANHUI BAIWO BIOTECHNOLOGY CO., LTD.'s registered trademark portfolio includes well-known marks such as GUSUSA. These are among 1 currently registered trademark in the portfolio.

What is ANHUI BAIWO BIOTECHNOLOGY CO., LTD.'s trademark registration success rate?

ANHUI BAIWO BIOTECHNOLOGY CO., LTD. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.